Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9753 - 9760 of 12086 results
Bayer Given a Headache by Trial Court Decision in FLANAX US Trademark Dispute
February 25, 2015| Blog| Viewpoint
Telehealth Bill Moving Forward in Florida-But Medicaid Coverage Sacrificed
February 25, 2015| Blog| Viewpoint
FTC-DOJ Workshop on Health Care Competition Enters Second Day
February 25, 2015| Blog| Viewpoint
The YouTube Kids app is here! Now what?
February 25, 2015| Blog| Viewpoint
The Court's Decision in the FLANAX US Trademark Dispute Gives Bayer a Headache
February 25, 2015| Blog| Viewpoint
Workplace Challenges in 2015, Part 3 of 5: Beware of Stop-Loss Coverage Gaps When Choosing a Self-Funded Major Medical Plan
February 24, 2015| Blog| Viewpoint
ACA Countdown to Compliance For Employers - Complete Volume Available
February 24, 2015| Blog| Viewpoint
Apply Now for Cleantech Open Northeast's 2015 Start-Up Accelerator Program
February 24, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|